Unlocking the Promise of Cell Therapy

T-Cell Engineering Reimagined

A therapeutic pipeline targeting unmet clinical needs in Oncology and Autoimmune disease

Clinical Stage Cell Therapy Company

NEXT GENERATION CELL THERAPY
TECHNOLOGY

Incorporates the latest technological advancements in cell therapy & gene editing by field-leading pioneers.

PROPRIETARY SENZA5™ PLATFORM TECHNOLOGY

Unprecedented utility and superior anti-tumor efficacy across multiple distinct liquid & solid tumor models.

CLINICAL STAGE
LEAD PROGRAM

VIPER-101 program designed to address significant unmet need in T-cell lymphoma.

Lead program is moving into the clinic with POC human data expected in 2024

1Evaluate pharma- consensus forecasts; week of 2/20/23

CAR T-cell therapy has shown the greatest potential for curative outcomes of any cancer therapy in history — but limitations remain

Six approved CAR T cell products expected to generate
>$4B in 2024 (>25% CAGR through 2028)1

However, approved indications limited to B-cell malignancies, and progression free survival is not achieved for most patients

Current limitations create enormous unmet need; robust opportunity exists

Vittoria is Dedicated to Overcoming Current CAR T-cell Therapy Limitations

CURRENT LIMITATION

OUR SOLUTION

Limited indications

Cell therapies target
just 5% of cancers

Treat more indications

By unlocking CAR-T efficacy for difficult to treat diseases in both oncology and autoimmune indications

Modest efficacy

Progression-free survival <40%

Improve efficacy

with the utilization of novel gene editing technologies

Toxicity & Manufacturing issues

Approved cell therapies are associated with prolonged/permanent B-cell aplasia

Enhance specificity + safety

by preventing on-target aplasia, lowering dosing, reducing vein-to-vein times, specifically targeting malignant cells

Vittoria Aims to Overcome Current CAR T Cell Therapy Limitations

CURRENT LIMITATION

Limited indications

Currently cell therapies target
just 5% of cancers

OUR SOLUTION

Treat more indications

Cancer & Autoimmunity: by expanding antigenic targets

CURRENT LIMITATION

Modest efficacy

Progression-free survival <40%

OUR SOLUTION

Improve efficacy

via utilization of novel gene editing technologies

CURRENT LIMITATION

Toxicity & Manufacturing issues

Cell therapies are associated with prolonged/permanent B cell aplasia

OUR SOLUTION

Enhance specificity + safety

by preventing on-target aplasia, lowering dosing, reducing vein-to-vein times, specifically targeting malignant cells

Senza5™: first-in-class CAR T-cell therapy platform combining the power of genetic engineering and a proprietary five-day manufacturing process

Harnessing the unrealized potential of CD5 as a novel checkpoint for cell therapies using gene editing:

Augment effector function by utilizing gene editing of the CD5 signaling pathway to exploit its immuno-modulatory properties

Enhance early CAR-T in vivo expansion and functional persistence by enhancing “stemness” and durability

Deliver superior anti-tumor efficacy in both liquid and solid tumor animal models versus conventional cell therapies

Improve patient outcomes by lowering dosing requirements, reducing manufacturing failures, and expanding successful applications of engineered T-cell therapies

VIPER-101: Gene-edited, Autologous, Dual Population CAR T-cell therapy for T-cell Lymphoma; CD5 knockout, anti-CD5 chimeric antigen receptor T-cell developed using Senza5

T-cell lymphoma is a progressive disease with poor prognosis and significant unmet clinical need

Source: Adapted from Mordor Intelligence  |  Data from UK Haematology Malignancy Research Network Smith et al. Br J Cancer (2015) 112, 1575-1584

Working to overcome current CAR T cell therapy limitations

WE PLAN TO ACHIEVE RAPID CELL THERAPY MARKET PENETRATION BY:

Generating POC clinical data for our Viper 101 lead program in a cost-effective manner. Will validate safety and efficacy of both Viper 101 and Senza5 platform technology.
Expect expedited path to approval

Employing novel gene editing technologies (NGET) via a strategic partnership with industry leader Metagenomi to power a pipeline of next-generation gene-edited cell therapy assets

Developing pipeline programs to exploit our enabling technologies and generate highly differentiated, innovative cellular therapeutics

Harvesting the utility of our platform technologies to drive paradigm-shifting improvements in cell therapy dosing, delivery, pre-conditioning regimens and vein-to-vein times

Leveraging Viper 101 POC clinical data to attract strategic partners and explore monetizing lead program and platform technologies via out-licensing

Cell Therapy Market est. CAGR FY21-FY30

Capital-efficient leadership team with vast pharmaceutical, entrepreneurial, scientific and clinical experience

MANAGEMENT TEAM

Nicholas Siciliano, Ph.D.

Chief Executive Officer,
Co-Founder & Director

Rosemary Mazanet, M.D., Ph.D.

Chief Medical Officer

Aditya Nimmagadda, P.M.P

Sr. Director, CMC

Adam Snook, Ph.D.

Head, Preclinical Development

Steven Yang, M.D., Ph.D

Director, Laboratory Operations

Lori Forrest, C.P.A.

Sr. Controller

BOARD OF DIRECTORS

Nicholas Siciliano, Ph.D.

Chief Executive Officer,
Co-Founder & Director

Bruce Peacock

Co-Founder & Chairman

Lonnie Moulder, M.B.A.

Director

Preston Noon, Pharm.D., M.B.A.

Director

Sebastian Bernales, Ph.D.

Observer
General Partner, Humboldt Fund

R. Carter Caldwell

Observer
Director of Penn Medicine
Co-Investment Fund

Scientific & clinical advisors

Dr. Marco Ruella, M.D.

Scientific Founder & SAB Chair

Dr. Carl June, M.D.

Scientific Advisor

Dr. Michael Kalos, Ph.D.

Scientific Advisor

Dr. Jian Irish, Ph.D.

Scientific Advisor

Dr. Stephen Schuster, M.D.

Scientific Advisor

Dr. Stefano Pileri, M.D., Ph.D.

Scientific Advisor

Dr. Stefan Barta, M.D.

Principal Investigator, Clinical Trial